Atea Pharmaceuticals (AVIR) News Today $4.15 +0.01 (+0.24%) Closing price 04:00 PM EasternExtended Trading$4.16 +0.00 (+0.12%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVIR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Atea Pharmaceuticals Inc (AVIR) Q1 2026 Earnings Call Highlights: Strategic Advancements and ...May 14, 2026 | finance.yahoo.comAtea Pharmaceuticals Announces Three Accepted Abstracts for Presentation at EASL Congress 2026May 13, 2026 | quiverquant.comQAtea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis PipelineMay 13, 2026 | globenewswire.comAtea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comAtea Pharmaceuticals Q1 Earnings Call HighlightsMay 12, 2026 | marketbeat.comAtea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 12, 2026 | globenewswire.comAtea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on TuesdayMay 5, 2026 | marketbeat.comAtea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026May 5, 2026 | globenewswire.comAtea Pharmaceuticals (AVIR) price target increased by 25.00% to 10.20April 29, 2026 | msn.comAtea Pharmaceuticals (NASDAQ:AVIR) Stock Price Up 1.6% - Still a Buy?April 23, 2026 | marketbeat.comAtea Pharmaceuticals (AVIR) price target increased by 33.33% to 8.16March 27, 2026 | msn.comAtea Pharmaceuticals’ Earnings Call Flags Pivotal 2026March 12, 2026 | theglobeandmail.comAnalysts Conflicted on These Healthcare Names: Atea Pharmaceuticals (AVIR), InnovAge Holding (INNV) and Kura Oncology (KURA)March 7, 2026 | theglobeandmail.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2025 earnings call transcriptMarch 7, 2026 | msn.comAtea Pharmaceuticals, Inc.: Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 6, 2026 | finanznachrichten.deAtea Pharmaceuticals Inc (AVIR) Q4 2025 Earnings Call Highlights: Advancing HCV Treatments and ...March 6, 2026 | finance.yahoo.comAtea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call TranscriptMarch 5, 2026 | seekingalpha.comAtea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 5, 2026 | globenewswire.comInsights Ahead: Atea Pharmaceuticals's Quarterly EarningsMarch 4, 2026 | benzinga.comAtea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026February 26, 2026 | globenewswire.comAtea Pharmaceuticals, Inc.: Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026February 24, 2026 | finanznachrichten.deAtea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026February 24, 2026 | globenewswire.comAtea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 15, 2026 | seekingalpha.comBullish Atea Pharmaceuticals Insiders Loaded Up On US$5.40m Of StockJanuary 13, 2026 | finance.yahoo.comAtea Pharmaceuticals to highlight strategic priorities for FY26January 9, 2026 | finance.yahoo.comAtea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2026 | globenewswire.comAtea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2026 | globenewswire.comAtea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026December 23, 2025 | seekingalpha.comAtea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C VirusDecember 22, 2025 | globenewswire.comWe're Keeping An Eye On Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn RateDecember 10, 2025 | finance.yahoo.comAtea Pharmaceuticals Inc (AVIR) Q3 2025 Earnings Call Highlights: Strategic Advances in HCV ...November 19, 2025 | finance.yahoo.comAtea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare ConferenceNovember 19, 2025 | globenewswire.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2025 Earnings Call TranscriptNovember 14, 2025 | insidermonkey.comAtea Pharmaceuticals’ Earnings Call Highlights Progress and OptimismNovember 14, 2025 | msn.comAtea Pharmaceuticals, Inc. (AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements TranscriptNovember 13, 2025 | seekingalpha.comAtea Pharmaceuticals Advances Antiviral Programs with New DataNovember 12, 2025 | tipranks.comAtea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call TranscriptNovember 12, 2025 | seekingalpha.comAtea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business UpdateNovember 12, 2025 | globenewswire.comAtea Pharmaceuticals announces presentation of data on BEM, RZRNovember 8, 2025 | msn.comAtea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C ...November 8, 2025 | markets.businessinsider.comAtea Pharmaceuticals Presents Promising Modeling Data for Bemnifosbuvir and Ruzasvir Combination Therapy in Hepatitis C at The Liver Meeting 2025November 7, 2025 | quiverquant.comQAtea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025November 7, 2025 | globenewswire.comAtea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025November 5, 2025 | globenewswire.comAtea Pharmaceuticals Advances with Key Phase 1 Study on Bemnifosbuvir/RuzasvirOctober 27, 2025 | tipranks.comAtea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025October 22, 2025 | globenewswire.comAtea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at ...October 7, 2025 | finance.yahoo.comAtea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025October 7, 2025 | globenewswire.comAtea Pharmaceuticals, Inc. (AVIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comAtea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare ConferenceSeptember 2, 2025 | globenewswire.comAtea Pharmaceuticals’ Earnings Call Highlights HCV ProgressAugust 13, 2025 | msn.com Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AVIR Media Mentions By Week AVIR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVIR News Sentiment▼0.790.39▲Average Medical News Sentiment AVIR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVIR Articles This Week▼42▲AVIR Articles Average Week Get the Latest News and Ratings for AVIR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Atea Pharmaceuticals and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies MBX Biosciences News Palvella Therapeutics News Harmony Biosciences News Zymeworks News Agios Pharmaceuticals News Intellia Therapeutics News Nuvation Bio News Vericel News Recursion Pharmaceuticals News Nurix Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVIR) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
